In episode 3 of our new series with SRNA, Dr. Greenberg and Bennett discuss the diagnosis, acute treatment, and long-term management of MOGAD, highlighting current therapies and ongoing research. Watch here: neurologylive.com/view/understan…

Excited to be back at #ECTRIMS in Copenhagen- looking forward to learning and collaboration with colleagues. Follow for updates from #ECTRIMS2024 #MS #NMOSD #MOGAD

Dr. Okuda: Risk factors at the time of RIS that increase risk of going on to develop #MS #ECTRIMS2024

Moccia: the 2024 McDonald criteria will result improved imaging protocols: SWI for CVS and PRL, Spinal cord MRI, imaging optic nerve, CSF with OB and kFLC #ECTRIMS2024

Kuchling: A cohort of 11.6% of patients with #NMDA receptor encephalitis also had overlap with #MS - A call to carefully review MRI in these patients.

Does simvastatin actually work for progressive multiple sclerosis? We will find out soon. This is the MS-STAT2 protocol, a multicenter, randomized controlled, double-blind, phase 3 clinical trial in the UK. Authors include @GavinGiovannoni pubmed.ncbi.nlm.nih.gov/39284697/

Riley Bove (US) showed that treatment with Ocrelizumab during lactation is SAFE! Negligible transfer in the milk and no effect in serum of the infants. (SOPRANINO study) No reason to postpone the treatments. Nice to see that confirmation #ECTRIMS2024

Thouvenot: Largest therapeutic trial of vitamin D therapy in #MS. Oral vitamin D 100,000 IU every two weeks reduced disease activity by 34% in CIS patients and in early RRMS. #ECTRIMS2024

Chataway: STAT-2 trial showed no benefit of simvastatin in slowing disability progression in #SPMS #ECTRIMS2024

Dr Oh: GEMINI I & II - no difference in ARR between teriflunomide and tolebrutinib, however, a 29% risk reduction in 6 month confirmed disability worsening for teriflunomide. #ECTRIMS2024 #BTKi

HERCULES phase 3: Tolebrutinib shows a 31% risk reduction in time to 6 month CDP in non-relapsing SPMS #ECTRIMS2024

The kappa free light chains index (cut-off 6.83) is 100% sensitive and 92% specific at differentiating paediatric #MultipleSclerosis from controls, and, if over 93.77, is 100% specific. Study from Hôpital Bicêtre AP-HP Université Paris Cité ▶️ journals.sagepub.com/doi/full/10.11…

Transplanting genetically engineered OPCs, which give rise to myelin-making cells, boosted myelin repair in mice with brain lesions. bit.ly/3UcbEtu #news

🌞🌊This morning at the 2025 #ACTRIMSForum, we had a conversation with Jacqueline Nicholas MD MPH, of OhioHealth, who talked about using modern tools and frameworks to reengineer #MultipleSclerosis management. Be on the lookout for the interview coming soon! ACTRIMS® 🧠🎥

✂️📹 In this short video clip, Jacqueline Nicholas MD MPH, of OhioHealth, highlighted the connection aspect of attending #ACTRIMSForum! ACTRIMS® #MS #MultipleSclerosis 🌴🌊

"If approved, #tolebrutinib would become the first and only brain-penetrant Bruton tyrosine kinase (#BTK) inhibitor marketed for the treatment of [#MultipleSclerosis], and the first specific for nrSPMS."

The Wellness Conversation:  Exploring Multiple Sclerosis nbc4i.com/daytime-columb… #MultipleSclerosis #OhioHealth #MSAwareness

It's #MS Awareness Month and we're talking about Women with #MS: @columbuspublichealth instagram.com/reel/DHopMqIyW…